What are the optimal imaging methods to determine extent of bone disease in newly diagnosed MM?

Update: 2017-09-27

Description

Dr. Ruben Niesvizky discusses newer approaches for imaging in patients who have multiple myeloma with bone disease, including the benefits of combining modalities such MRI and PET scan.

Comments

In Channel

Third-generation FLT3 inhibitors in clinical development

2018-10-2602:42

CAR T case study in acute myeloid leukemia

2018-10-0505:49

Key considerations when prescribing midostaurin with a strong CYP3A4 inhibi

2018-10-0502:23

How to proceed with a patient who presents with idiopathic cytopenia of undetermined significance

2018-03-2003:58

When to consider iron chelation therapy for a transplant-eligible patient

2018-03-2003:56

53-year-old woman presenting with severe fatigue and bruising

2018-03-2003:58

New subcategories of pancreatic cancer allow for a biomarker-driven approach to therapy

2018-01-0504:00

What are the unique aspects of pancreas cancer that lead to the development of novel therapeutics?

2018-01-0502:40

Predictors of response to lenalidomide in a non-del(5q) MDS patient

2018-01-0503:03

What are the pros and cons of radiation therapy?

2017-12-2102:29

What defines high-quality survivorship care for patients treated for classical Hodgkin lymphoma?

2017-11-3003:01

Second primary malignancies associated with lenalidomide maintenance

2017-11-3002:53

Impact of consolidation therapy in patients post-transplant

2017-11-3003:09

Bortezomib as an alternate strategy for maintenance therapy.

2017-10-2302:32

What may be the future role for brentuximab vedotin in newly diagnosed Hodgkin lymphoma?

2017-10-2302:35

Has MRD testing become a standard of care in multiple myeloma?

2017-10-2303:22

The Precision Promise [SM] Initiative: What is it designed to achieve?

2017-09-2704:32

Enasidenib in mutant-IDH2 R/R AML: Results of a phase 1 dose-escalation and expansion study